Novavax (NVAX) Competitors $6.67 +0.25 (+3.89%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. FOLD, LGND, BCRX, MNKD, CLDX, DVAX, INVA, OPK, GERN, and MYGNShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), OPKO Health (OPK), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Novavax vs. Amicus Therapeutics Ligand Pharmaceuticals BioCryst Pharmaceuticals MannKind Celldex Therapeutics Dynavax Technologies Innoviva OPKO Health Geron Myriad Genetics Novavax (NASDAQ:NVAX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Which has more volatility & risk, NVAX or FOLD? Novavax has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Is NVAX or FOLD more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Novavax's net margin of -32.18%. Amicus Therapeutics' return on equity of 12.44% beat Novavax's return on equity.Company Net Margins Return on Equity Return on Assets Novavax-32.18% N/A -17.05% Amicus Therapeutics -10.62%12.44%2.60% Does the media refer more to NVAX or FOLD? In the previous week, Novavax had 34 more articles in the media than Amicus Therapeutics. MarketBeat recorded 43 mentions for Novavax and 9 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.15 beat Novavax's score of 0.53 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 17 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Amicus Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, NVAX or FOLD? Amicus Therapeutics has lower revenue, but higher earnings than Novavax. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$682.16M1.56-$545.06M-$1.33-4.99Amicus Therapeutics$528.30M4.35-$151.58M-$0.18-41.58 Does the MarketBeat Community prefer NVAX or FOLD? Novavax received 319 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 74.06% of users gave Novavax an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote. CompanyUnderperformOutperformNovavaxOutperform Votes85174.06% Underperform Votes29825.94% Amicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% Do insiders & institutionals believe in NVAX or FOLD? 53.0% of Novavax shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend NVAX or FOLD? Novavax presently has a consensus price target of $18.00, suggesting a potential upside of 171.29%. Amicus Therapeutics has a consensus price target of $16.75, suggesting a potential upside of 123.78%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummaryAmicus Therapeutics beats Novavax on 10 of the 18 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$2.96B$5.52B$7.70BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-2.9429.6122.3418.30Price / Sales1.56491.10391.19102.96Price / CashN/A168.6838.1834.62Price / Book-1.103.176.674.19Net Income-$545.06M-$72.17M$3.22B$248.05M7 Day Performance-11.34%0.83%1.93%2.10%1 Month Performance-5.21%-2.44%-1.23%0.63%1 Year Performance53.23%-22.45%17.23%4.57% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax3.6128 of 5 stars$6.67+3.9%$18.00+169.9%+49.7%$1.07B$682.16M-2.951,990FOLDAmicus Therapeutics4.3627 of 5 stars$7.33-0.2%$16.75+128.4%-26.6%$2.25B$528.30M-40.64480Upcoming EarningsPositive NewsLGNDLigand Pharmaceuticals4.3868 of 5 stars$108.42+0.3%$146.43+35.1%+58.1%$2.09B$167.13M43.1980Positive NewsBCRXBioCryst Pharmaceuticals4.4519 of 5 stars$8.30-1.0%$15.57+87.5%+97.7%$1.73B$450.71M-13.60530Upcoming EarningsAnalyst ForecastMNKDMannKind3.1259 of 5 stars$4.72-0.5%$9.56+102.8%+15.3%$1.43B$285.50M67.36400Upcoming EarningsPositive NewsCLDXCelldex Therapeutics1.9659 of 5 stars$21.24+8.6%$55.30+160.3%-43.4%$1.40B$7.02M-8.21150Positive NewsDVAXDynavax Technologies4.182 of 5 stars$11.19+3.4%$20.50+83.3%+1.9%$1.37B$277.25M62.13350Upcoming EarningsNews CoverageINVAInnoviva4.209 of 5 stars$18.35+0.6%$55.00+199.7%+19.2%$1.15B$358.71M26.57100Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsOPKOPKO Health4.4732 of 5 stars$1.41-0.4%$2.75+95.7%+12.9%$943.53M$713.14M-7.394,200Earnings ReportShort Interest ↓Positive NewsGERNGeron3.9907 of 5 stars$1.40-1.8%$5.75+312.2%-66.7%$888.49M$76.99M-4.3670Upcoming EarningsMYGNMyriad Genetics4.0957 of 5 stars$7.41-0.2%$20.61+178.3%-63.6%$682.53M$837.60M-5.702,600Upcoming Earnings Related Companies and Tools Related Companies Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Innoviva Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVAX Stock Free NVAX Stock Alerts